PepGen doses first patient in Phase 1 FREEDOM-DM1 trial; data expected in 2024

PepGen Inc.

First patient dosed in Phase 1 FREEDOM-DM1 trial of PGN-EDODM1 for myotonic dystrophy type 1.
Safety, transcript splicing correction, and clinical outcome data at 5 mg/kg dose expected in 2024.
UK MHRA clearance obtained, enabling enrollment in third country (US, Canada, UK).
Trial to enroll ~24 adults; single ascending doses from 5 to 20 mg/kg with safety-based escalation.
CEO James McArthur calls dosing a significant milestone toward transformative therapy for DM1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.